The Revolution Apex™ CT Scanner – best image quality for EVERY patient

27th July 2020, Spectrum Radiology

one beat cardiac scan

General Electric (GE) set the standard for low-dose imaging back in 2008 with an iterative reconstruction technology capable of lowering dose by 50 percent. While that benchmark continues to change, GE introduced Deep Learning Image Reconstruction, a system which uses artificial intelligence to combine the low dose of iterative reconstruction with a “classic-looking” image texture of filtered back projection.…

Deleting ECG item numbers in primary care – whose idea was it?

27th July 2020, Dr Chee L Khoo

GP: the brains behind ECGs

Just pause and think for just one minute. Over the last 12 months, how many atrial fibrillations have you picked up incidentally on ECG? How many silent old acute myocardial infarct have you seen on ECG in a patient with diabetes? How many ST and T wave changes have you seen on ECG which suggest ischaemia which requires further investigations?…

Medical Nutritional Therapy – why are you not prescribing it?

26th July 2020, Dr Chee L Khoo

Whenever we think about management of hyperglycaemia in patients with type 2 diabetes (T2D), we usually think about the most efficacious hypoglycaemic agent we can find (and on the PBS). If you look carefully at most management guidelines, lifestyle measures appears at the very top of the algorithm, side by side metformin. Sadly, it is often not the most prominent and usually, dismissed as an important part of the treatment algorithm.…

Goose foot – how many “toes” does the goose foot have?

20th July 2020, Dr Chee L Khoo

Figure 1

This is not a riddle. I often ask my medical students and patients this question and they all look at me strangely. How does this relate to medical science? Of course, we are talking about pes anserinus (PA). For those of you who remember your anatomy, PA relates to the 3 tendons that are attached to the medial aspect of the knee.…

GLP-1 agonists – now we have 5

12th July 2020, Dr Chee L Khoo

One month ago, we discussed Ozempic®(semaglutide) as the new GLP-1 agonist kid on the block in the treatment of hyperglycaemia in patients with type 2 diabetes (T2D). We foreshadowed that it will be coming real soon. Well, sooner than I thought. Ozempic® went on the PBS on the 1st July. What we didn’t know was what the restrictions will be when prescribing for patients with T2D.…

Abbreviated breast MRI – how useful is it?

8th July 2020, Spectrum Radiology

Adjunct screening with dynamic contrast-enhanced (DCE)-MRI was first recommended for women at high (>20%) lifetime risk of breast cancer, facilitating earlier cancer detection and reducing interval cancers. Even in women at average risk of breast cancer, there is evidence that they might also benefit from screening MRI.

Apart from the cost of MRI equipment, other costs include the relatively long acquisition, limiting high-volume patient throughput and interpretation times involved in a full diagnostic protocol.…

Diabetic foot ulcers – out of sight, out of mind?

29th June 2020, Dr Chee L Khoo

diabetic foot

One in three patients with diabetes will develop diabetic foot ulcers (DFU). This typically occurs in the setting of peripheral artery disease, peripheral neuropathy and trauma. Foot ulcers invariably leads to lower extremity amputation (LEA) and both are associated with significant morbidity and mortality. We know that poor glycaemic control contributes to the development of DFU and LEA.…

T1D & T2D – different beginnings, same fate?

28th June 2020, Dr Chee L Khoo

In type 1 diabetes (T1D), the β-cell die rapidly from a massive immunological assault and practically all the β-cells are quickly lost and hence, there is an absolute deficiency of insulin secretion. Using auto-antibody screening, we can define T1D. Do you realise that we don’t actually have a definition for type 2 diabetes (T2D).…

Ozempic – another GLP-1 agonist coming real soon

12th June 2020, Dr Chee L Khoo

Whenever there are multiple brands of the same class of drugs on the market, one always wonder whether the new kid on the block is a “johnny-come-lately” trying to break into an already crowded market with yet another drug or it’s really a new kid with much better credentials. We already have 4 GLP-1 agonists in Australia and now a fifth one will be out real soon.…